Treatment patterns and outcomes for patients with advanced melanoma in US oncology clinical practices

Eric Whitman, Frank Xiaoqing Liu, Xiting Cao, Scott J. Diede, Amin Haiderali, Amy P. Abernethy

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Aim: To describe recent evolution in treatment patterns and outcomes for advanced melanoma (AMel). Methods: This retrospective observational study analyzed de-identified electronic health record data from the Flatiron Health database for 1140 adult patients who initiated first-line therapy for AMel from 1 January 2014 to 30 June 2016 with follow-up through 28 February 2017. Results: The most common first-line regimens were ipilimumab-based therapies (34%), anti-PD-1 monotherapy (26%) and BRAF/MEK inhibitor(s) (20%). First-line ipilimumab-based and BRAF inhibitor regimens decreased after the third quarter of 2014 (3Q2014), and by 2Q2016, 55 and 91% of BRAF-mutant and BRAF wild-type cohorts, respectively, received a first-line anti-PD-1 regimen. Median overall survival from first-line initiation for all patients was 18.8 months (95% CI: 16.3-23.3). Conclusion: Results illustrate changing paradigms of therapy and real-world patient outcomes for AMel.

Original languageEnglish (US)
Pages (from-to)459-471
Number of pages13
JournalFuture Oncology
Volume15
Issue number5
DOIs
StatePublished - Feb 1 2019

Fingerprint

Medical Oncology
Melanoma
Electronic Health Records
Mitogen-Activated Protein Kinase Kinases
Observational Studies
Therapeutics
Retrospective Studies
Databases
Survival
Health
ipilimumab

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Whitman, Eric ; Liu, Frank Xiaoqing ; Cao, Xiting ; Diede, Scott J. ; Haiderali, Amin ; Abernethy, Amy P. / Treatment patterns and outcomes for patients with advanced melanoma in US oncology clinical practices. In: Future Oncology. 2019 ; Vol. 15, No. 5. pp. 459-471.
@article{4cf11ff89d42418aa3791479b369ceb2,
title = "Treatment patterns and outcomes for patients with advanced melanoma in US oncology clinical practices",
abstract = "Aim: To describe recent evolution in treatment patterns and outcomes for advanced melanoma (AMel). Methods: This retrospective observational study analyzed de-identified electronic health record data from the Flatiron Health database for 1140 adult patients who initiated first-line therapy for AMel from 1 January 2014 to 30 June 2016 with follow-up through 28 February 2017. Results: The most common first-line regimens were ipilimumab-based therapies (34{\%}), anti-PD-1 monotherapy (26{\%}) and BRAF/MEK inhibitor(s) (20{\%}). First-line ipilimumab-based and BRAF inhibitor regimens decreased after the third quarter of 2014 (3Q2014), and by 2Q2016, 55 and 91{\%} of BRAF-mutant and BRAF wild-type cohorts, respectively, received a first-line anti-PD-1 regimen. Median overall survival from first-line initiation for all patients was 18.8 months (95{\%} CI: 16.3-23.3). Conclusion: Results illustrate changing paradigms of therapy and real-world patient outcomes for AMel.",
author = "Eric Whitman and Liu, {Frank Xiaoqing} and Xiting Cao and Diede, {Scott J.} and Amin Haiderali and Abernethy, {Amy P.}",
year = "2019",
month = "2",
day = "1",
doi = "10.2217/fon-2018-0620",
language = "English (US)",
volume = "15",
pages = "459--471",
journal = "Future Oncology",
issn = "1479-6694",
publisher = "Future Medicine Ltd.",
number = "5",

}

Treatment patterns and outcomes for patients with advanced melanoma in US oncology clinical practices. / Whitman, Eric; Liu, Frank Xiaoqing; Cao, Xiting; Diede, Scott J.; Haiderali, Amin; Abernethy, Amy P.

In: Future Oncology, Vol. 15, No. 5, 01.02.2019, p. 459-471.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Treatment patterns and outcomes for patients with advanced melanoma in US oncology clinical practices

AU - Whitman, Eric

AU - Liu, Frank Xiaoqing

AU - Cao, Xiting

AU - Diede, Scott J.

AU - Haiderali, Amin

AU - Abernethy, Amy P.

PY - 2019/2/1

Y1 - 2019/2/1

N2 - Aim: To describe recent evolution in treatment patterns and outcomes for advanced melanoma (AMel). Methods: This retrospective observational study analyzed de-identified electronic health record data from the Flatiron Health database for 1140 adult patients who initiated first-line therapy for AMel from 1 January 2014 to 30 June 2016 with follow-up through 28 February 2017. Results: The most common first-line regimens were ipilimumab-based therapies (34%), anti-PD-1 monotherapy (26%) and BRAF/MEK inhibitor(s) (20%). First-line ipilimumab-based and BRAF inhibitor regimens decreased after the third quarter of 2014 (3Q2014), and by 2Q2016, 55 and 91% of BRAF-mutant and BRAF wild-type cohorts, respectively, received a first-line anti-PD-1 regimen. Median overall survival from first-line initiation for all patients was 18.8 months (95% CI: 16.3-23.3). Conclusion: Results illustrate changing paradigms of therapy and real-world patient outcomes for AMel.

AB - Aim: To describe recent evolution in treatment patterns and outcomes for advanced melanoma (AMel). Methods: This retrospective observational study analyzed de-identified electronic health record data from the Flatiron Health database for 1140 adult patients who initiated first-line therapy for AMel from 1 January 2014 to 30 June 2016 with follow-up through 28 February 2017. Results: The most common first-line regimens were ipilimumab-based therapies (34%), anti-PD-1 monotherapy (26%) and BRAF/MEK inhibitor(s) (20%). First-line ipilimumab-based and BRAF inhibitor regimens decreased after the third quarter of 2014 (3Q2014), and by 2Q2016, 55 and 91% of BRAF-mutant and BRAF wild-type cohorts, respectively, received a first-line anti-PD-1 regimen. Median overall survival from first-line initiation for all patients was 18.8 months (95% CI: 16.3-23.3). Conclusion: Results illustrate changing paradigms of therapy and real-world patient outcomes for AMel.

UR - http://www.scopus.com/inward/record.url?scp=85060922048&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060922048&partnerID=8YFLogxK

U2 - 10.2217/fon-2018-0620

DO - 10.2217/fon-2018-0620

M3 - Article

C2 - 30251550

AN - SCOPUS:85060922048

VL - 15

SP - 459

EP - 471

JO - Future Oncology

JF - Future Oncology

SN - 1479-6694

IS - 5

ER -